Inside My Portfolio Part II: 15 More Positions I'm Holding
Here are 15 more stocks I'm trading as we close out 2025.
You're reading 0 of 1 free page.
Register to read more or Unlock Pro — 50% Off Ends Soon
Market action is mixed on Friday, with big caps leading and small caps lagging. The Russell 2000 is down 0.6% while the Nasdaq 100 (QQQ) is up 0.2%. Breadth is running negative, and volume is light. There currently are no signs of a Santa Rally, and I'm not making any big moves today.
On Wednesday, I updated 16 stocks in my portfolio. Here is an update on 15 more. It is important to note that I am an aggressive trader and my positions in these stocks are constantly changing. Some of these positions are small and are established for tracking purposes, while others are bigger as I expect favorable catalysts in the near term.
Here are 15 more positions I am currently holding:
Humacyte (HUMA) . After a long period of disappointment, HUMA now has an approved artificial vein product and financing in place. It has started initial sales and has other indications underway, but management needs to prove itself at this point. There is likely limited downside, but it will have to start surpassing expectations to move the stock.
Bitcoin (IBIT) has been under extreme pressure since hitting new highs in early October. Since there are no fundamentals, Bitcoin is cyclical and trades primarily on technical patterns. The bears are currently in control, but I expect the boom-bust cycle to continue, and there will be another strong upside run at some point in 2025. I'm holding a long-term position and waiting for a long-side trade to develop.
Invivyd (IVVD) is a little biotech in the vaccine area that will have key data around mid-year 2026. The chart looks promising, and I expect it to see positive anticipation. There is no immediate short-term catalyst, but the chart is good.
Mind Medicine (MNMD) is another biotechnology name that has gained traction in the psychiatric field. This move is due in part to the rescheduling of cannabis and the greater acceptance of non-traditional drugs for medical purposes. The chart is solid and expect this theme to continue. Other stocks in the group are Cybin (CYBN), Alto Neurosciences (ANRO) , and Compass (CMPS).
Mereo BioPharm (MREO) has extremely important data coming any day. This is a binary event, and the stock will likely either double or be cut in half. The news will create some significant volatility that I plan to trade.
Ocular (OCUL) management has made a move to accelerate Food and Drug Administration approval of a key drug. The stock spiked on the news and is now pulling back to support at the 50-day moving average. I'm looking for some positive anticipation to build again early in 2026
Ondas (ONDS) is a drone play that has been announcing a steady stream of contracts. The chart looks solid, and I expect the theme to continue.
Purecylce (PCT) owns technology for plastic recycling. As I recently noted, a new board member for the Mars family will be for adoption of the technology, and I expect that progress with both facilities and contracts will drive the stock higher.
Prothena (PRTA) is a rare earth mining play. It is still in development, but I expect that the start of operations will drive the stock higher in 2026.
uniQure (QURE) was the victim of changes at the FDA in 2025. It went from $15 to $70 and back to $20 due to shifts in FDA policy. There appears to be some progress in clarifying the situation, and there is a clear need for the QURE product in Huntington's Disease. Any development with the FDA could drive the stock higher.
Rocket Pharm (RCKT) has also been under pressure due to the FDA, but has started to show some signs of progress. It has a number of programs in place that should advance in 2026
Sensus Healthcare (SRTS) provides equipment that uses superficial radiation for the treatment of skin cancer. Recently, there has been a major change in insurance reimbursement that should be a very positive catalyst, but management needs to perform before there will be more confidence in the stock.
Uber Technologies (UBER) is being treated as if Tesla (TSLA) will drive it out of business as its Robotaxi business develops. I believe the extreme pessimism is unjustified and that the stock will recover as it becomes clear that Uber will remain highly competitive regardless of changes in technology.
Viking Therapeutics (VKTX) is on track for the development of an oral obesity drug with exceptional characteristics. It will not be the first oral obesity drug, but it may be the best, and there is still some hope of an acquisition deal.
Xeris (XERS) was a winner in 2025 and should continue to produce strong revenue growth in 2026. It is at the early stages of development of a drug with a billion-dollar market, and the stock will move as progress is made. Analysts have not issued any estimates yet for this new drug, but once that starts, it should drive the target price higher. The stock will likely stay in a trading range for a while as investors await some news announcements.
At the time of publication, DePorre was long ANRO, HUMA, IBIT, IVVD, MNMD, MREO, OCUL, ONDS, PCT, PRTA, QURE, RCKT, SRTS, UBER, VKTX, XERX.
